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article under the CC BY-NC-ND license (Abstract Background/purpose: The prevalence of peri-implant diseases, including peri-
implant mucositis and peri-implantitis, is increasing. The aim of this study was to elucidate
the pathological mechanisms of inflammation and alveolar bone resorption in peri-implant tis-
sues. To do this, we fabricated inflamed gingiva around mini-implants in the palatine processes
of rats using lipopolysaccharide derived from Porphyromonas gingivalis (P.g-LPS).
Materials and methods: Pure titanium mini-implants were implanted into the palatine pro-
cesses of rats, and then intermittent injections of P.g-LPS were made into the gingival tissues
surrounding the mini-implants. The expression patterns of tumor necrosis factor-a, inter-
leukin-1b, chemokine (CeC motif) ligand 2, receptor activator of nuclear factor kB ligand
(RANKL), and osteoprotegerin (OPG) in the tissues were examined using real-time reverse tran-
scriptase polymerase chain reaction or enzyme-linked immunosorbent assays. Immunohisto-
chemical analysis was also performed to compare the T and B cells expressing RANKL.
Results: P.g-LPS increased the expressions of tumor necrosis factor-a, interleukin-1b, chemo-
kine (CeC motif) ligand 2, and RANKL in the gingival tissues surrounding the mini-implants. In
contrast, the expression of OPG in the P.g-LPS samples was decreased. Consequently, the
RANKL/OPG ratio was significantly increased. Moreover, cells stained positively for both




on for Dental Sciences of the Republic of China. Published by Elsevier Taiwan LLC. This is an open access
http://creativecommons.org/licenses/by-nc-nd/4.0/).
RANKL/OPG ratio in peri-implant gingiva 9Conclusion: These data revealed that P.g-LPS injections increased the RANKL/OPG ratio in the
gingival tissues surrounding mini-implants in the rat model. In addition, the CD3-positive cells
in the gingival tissues injected with P.g-LPS expressed RANKL. This suggests that the activated
T cells capable of infiltrating gingival tissues affected by P.g-LPS may be one of the sources of
RANKL and may also be involved in the disease progression from peri-implant mucositis to peri-
implantitis.
Copyright ª 2015, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Dental implant therapy is currently viewed as a treatment
modality with a high success rate. However, peri-implant
mucositis and peri-implantitis caused by bacterial in-
fections and excessive implant loading remain serious
issues.1e6 The emergence of peri-implantitis resulting in
bone resorption has been observed and found problematic
since the oral implant system, initially proposed by a
Swedish group, was established. The number of reports on
peri-implantitis has gradually increased. Although the
general prevalence of peri-implant diseases is difficult to
assess, it has been reported that 20% of patients undergoing
implant treatment develop peri-implantitis,7 and close to
80% of those patients present with symptoms of peri-
implant mucositis.8
Peri-implant mucositis is an inflammation that is limited
to the mucosa, while peri-implantitis affects the implant-
supporting alveolar bone.9 Peri-implant mucositis is thought
to be a reversible condition, unlike peri-implantitis.9
Because oral bacteria can colonize almost instantly after
implantation, we focused on understanding peri-implant
mucositis caused by bacterial infection for the purpose of
finding preventive therapies. Although bacterial infections
around implants are well known as the main causes of peri-
implant mucositis and peri-implantitis,3 the mechanisms of
these diseases remain unclear.
Many microbiological studies of dental implants with
healthy and diseased marginal peri-implant tissues in
humans10e12 and animals13,14 have been published. These
reports show that Gram-negative bacilli, such as Porphyr-
omonas gingivalis, Treponema denticola, and Tannerella
forsythia, similar to those found in periodontal disease, can
be detected in peri-implant pockets.12e17 These microor-
ganisms are strongly suspected of contributing to peri-
implant diseases accompanied with inflammation and/or
bone destruction.
Osteoclasts play an important role in the bone resorption
associated with periodontitis, which is mediated by re-
ceptor activator of nuclear factor kB ligand (RANKL).18 A
decoy receptor of RANKL, osteoprotegerin (OPG) produced
by osteoblasts, inhibits the RANKL/RANK signals and oste-
oclast formation.19 Therefore, in this study, we assessed
the RANKL/OPG expression ratio in the peri-implant tissues
because it is crucial for the regulation of bone resorption.
Recently, interest in osteoimmunology, the study of in-
teractions between immune cells and the skeletal system,
has increased.20 In fact, RANKL was already detected in thesynovial fibroblasts and T cells in the inflamed joints of
rheumatoid arthritis patients.21 T cells expressing CD3 may
also infiltrate the affected gingival tissue in peri-
implantitis, as well as in periodontitis.22 However,
whether these activated T cells involved in peri-implantitis
express RANKL or not remains unclear. CD20 antibody
therapy for auto immune and inflammatory diseases has
been tried over the past few years because of an increasing
number of reports indicating that B cells are involved in
those diseases.23 Therefore, to determine whether lym-
phocytes expressing CD3 or CD20 in the tissues of peri-
implant mucositis and peri-implantitis also express RANKL,
we developed a rat model of peri-implant mucositis
induced with lipopolysaccharide (LPS) derived from P. gin-
givalis, which has been previously reported to exist in the
peri-implant pocket. The most often used method to induce
alveolar bone resorption when creating a periodontitis
model is ligature. However, an infection model using peri-
odontal pathogens better mimics the clinical condition,
allowing for more accurate evaluations of the disease.
Thus, an LPS-induced model was used in the present study.
Materials and methods
Materials
Pure titanium mini-implants (diameter: 2 mm, length:
4 mm; Kondo Technology, Tokyo, Japan) were purchased
and used in this study.24 The mini-implants were washed
with acetone and ethanol in an ultrasonic bath for 30 mi-
nutes and autoclaved before use. LPS derived from P. gin-
givalis (P.g-LPS) was purchased from InvivoGen (San Diego,
CA, USA). The LPS was diluted with sterile endotoxin-free
water and stored at 20C until use.
Implantation of the mini-implant into a rat palatine
process
Eight-week-old Wistar rats (Kyudo. Co., LTD, Fukuoka,
Japan) were used for this animal study. The animal selec-
tion, management, anesthesia, and surgical and analysis
procedures were approved by the Animal Care and Use
Committee of Kyushu University (No. A25-138; Fukuoka,
Japan). The in vivo experiments using the rat model were
performed in accordance with the procedures allowed by
the committee. In brief, the rats were carefully anes-
thetized with sevoflurane and pentobarbital. Prior to


































10 T. Shuto et albeginning surgery, the implantation site was disinfected
with 10% iodine. A mini-implant was then placed into the
palatine process of the maxilla using micro drivers, and the
recipient gingival site was tightly sutured. After the gingival
tissues had healed, tridaily intermittent injections of P.g-
LPS (100 mL of 1 mg/mL per injection) were made into the
gingival tissues surrounding the mini-implant (nZ 6 rats for
each experimental endpoint). The same volume of
phosphate-buffered saline (PBS) was injected instead of
P.g-LPS into the control samples (n Z 6 rats for each
experimental endpoint). Each animal received only one
implant. For real-time reverse transcriptase polymerase
chain reaction (RT-PCR) and enzyme-linked immunosorbent
assay (ELISA) analysis, the gingival tissues and alveolar bone
from the samples were collected and divided into halves
after 6 hours (6 h), 4 days (4 d), and 14 days (14 d). Each of
the following analysis experiments were independently
repeated using the two sample halves to ensure accuracy
(i.e., n Z 6 biological replicates and n Z 2 technical rep-







Note. Forward primers (Primer F). reverse primers (primer R)
and probes are listed.
CCL2 Z chemokine (CeC motif) ligand 2; IL-1b Z interleukin-
1b; OPG Z osteoprotegerin; RANKL Z receptor activator of
nuclear factor kB ligand; RT-PCR Z reverse transcriptase po-
lymerase chain reaction; TNF-a Z tumor necrosis factor-a.Real-time quantitative RT-PCR analysis
Total ribonucleic acid (RNA) was extracted from the
gingival tissues and alveolar bone from the P.g-LPS samples
collected after 6 h, 4 d, and 14 d using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA). First-strand complemen-
tary deoxyribonucleic acid (cDNA) was synthesized from the
total RNA (100 ng) using ReverTra Ace (Toyobo, Osaka,
Japan). The cDNA was then amplified with BIOTAQ DNA
polymerase (Bioline, Randolph, MA, USA).25 Real-time
quantitative RT-PCR analyses for tumor necrosis factor-a
(TNF-a), interleukin-1b (IL-1b), chemokine (CeC motif)
ligand 2 (CCL2), RANKL, OPG, and b-actin were performed
using a Rotor-Gene 6000 (Qiagen, Tokyo, Japan). Beta-actin
was chosen as an internal control to normalize the vari-
ability in amplification caused by slight differences in the
total starting RNA concentrations. The sequences of
primers and probes for TNF-a, IL-1b, CCL2, RANKL, and OPG
used in the present study are listed in Table 1. The se-
quences of the primers and probe used for b-actin have
been described previously.26ELISA
The samples collected from the gingival tissues and alveolar
bone surrounding the mini-implants were placed in RIPA
buffer (Thermo Fisher Scientific, Yokohama, Japan). Tissue
debris was removed by centrifugation at 12,000g for 5 mi-
nutes at 4C. Then, the supernatants were transferred to
new microtubes. Next, the contents of CCL2, RANKL, and
OPG in the samples were assessed using commercially
available ELISA kits (DuoSet ELISA Development System,
R&D Systems, Minneapolis, MN, USA) following the manu-
facturer’s protocol. The protein content was estimated
using a Coomassie Plus Assay Kit (Thermo Fisher Scientific),
and the optical density was measured at 595 nm in a
microplate reader (Infinite M200, Tecan, Kanagawa, Japan)
according to the manufacturer’s instructions. The concen-
trations of CCL2, RANKL, and OPG in the supernatant of thetissue homogenates were normalized to the total protein
level.Immunofluorescent analysis
Gingival tissue samples isolated from the areas surrounding
the mini-implants were fixed with 4% paraformaldehyde
and then rinsed three times with PBS. After dehydration in
graded alcohol concentrations, the samples were
embedded in paraffin, serial sectioned (10-mm thick), and
mounted on glass slides. The deparaffinized sections were
incubated in a heated antigen retrieval solution (HistoVT
One, Nacalai Tesque, Kyoto, Japan) for 20 minutes at 90C
and then blocked with EzBlock BSA (ATTO, Tokyo, Japan)
for 30 minutes. Next, the sections were incubated with
primary antibodies against CD3 and CD20, which are surface
molecules specifically expressed on T and B cells, soluble
RANKL (sRANKL), and toll-like receptor 4 (TLR-4) overnight
at 4C and then with fluorescent-conjugated secondary
anti-mouse immunoglobulin (Ig)M (Alexa Fluor555, Invi-
trogen, Carlsbad, CA, USA) to CD3, anti-mouse IgG
(DyLight549, KPL, Baltimore, MD, USA) to CD20 and to TLR-
4, and anti-rabbit IgG (CF488A, Biotium, Hayward, CA, USA)
to sRANKL for 30 minutes at room temperature. After
rinsing three times with PBS, the tissue sections were
counterstained with 40,6-diamidino-2-phenylindole
(Dojindo, Kumamoto, Japan) for 10 minutes. Control IgG
(Mouse IgG, whole molecule; Rockland, Philadelphia, PA,
Figure 1 (A, a) Photograph of the mini-implant used in the present study. (b, c) One mini-implant was placed into the palatine
process of the maxilla of each rat. (B) Summary of the timeline for implantation, injection of lipopolysaccharide derived from
Porphyromonas gingivalis (P.g-LPS), and collection of samples is shown. Implantation was performed 7 days before the injection of
P.g-LPS (7 days and 0 days, respectively). Samples were collected at 6 hours (6h), 4 days (4d), and 14 days (14d) after the first
injection of P.g-LPS.
Figure 2 Effects of lipopolysaccharide derived from Porphyromonas gingivalis (P.g-LPS) on the mRNA expression levels of tumor
necrosis factor-a (TNF-a), interleukin-1b (IL-1b), chemokine (CeC motif) ligand 2 (CCL2), receptor activator of nuclear factor kB
ligand (RANKL), and osteoprotegerin (OPG) in the (A) gingival tissue and (B) bone surrounding the implants were examined by real-
time quantitative reverse transcriptase polymerase chain reaction. The mRNA levels were normalized to the expression levels of b-
actin mRNA. One site per animal was prepared, and six animals were assessed per group per endpoint. Two independent exper-
iments, each using the samples in triplicate, were performed. Data are presented as mean  standard deviation. *P < 0.05.
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12 T. Shuto et alUSA), rabbit IgG, or IgM (Purified Mouse IgM, kIsotype Ctrl;
BioLegend, San Diego, CA, USA) was used as a control
immunoglobulin for each antibody. Fluorescence images
were acquired with a BZ-9000 (Keyence, Osaka, Japan).
Data analysis
The significance of differences between the mean group
values was assessed using Student t tests. SPSS software
(version 20.0; IBM, Tokyo, Japan) was used for this statis-
tical analysis.Results
Effect of P.g-LPS on the expression of cytokines
related to inflammation and bone resorption in the
gingival tissue and bone surrounding the mini-
implants
To examine the effect of P.g-LPS on the cytokine expression
associated with inflammation and bone resorption, we
developed a model in which mini-implants were placed into
a rat maxilla (Figure 1A). The timeline of P.g-LPS injectionFigure 3 Effects of lipopolysaccharide derived from Porphyromon
motif) ligand 2 (CCL2), receptor activator of nuclear factor kB ligan
and (B) bone surrounding the implants were measured with enzy
protein content. One site per animal was prepared, and six anim
experiments, each using the samples in triplicate, were performedand sample collection are shown in Figure 1B. The
messenger RNA (mRNA) expression profiles of TNF-a, IL-1b,
CCL2, RANKL, and OPG in the tissues surrounding the mini-
implants were investigated after the gingival tissues were
injected with P.g-LPS. At 6 h after P.g-LPS injection, the
mRNA expression of the inflammation-inducing factors TNF-
a and IL-1b and the osteoclast-inducing factors CCL2 and
RANKL in the gingival tissues injected with P.g-LPS was
increased compared with those in the gingival tissues
without P.g-LPS, but only the increase in IL-1b was signifi-
cant (t test, P < 0.05; Figure 2A). After 14 d, the mRNA
expression of RANKL was significantly increased with P.g-
LPS (t test, P < 0.05; Figure 2A). By contrast, OPG was
significantly decreased at 14 d after the P.g-LPS-injection (t
test, P < 0.05). In bone, although all of the cytokines
examined, except IL-1b, were increased, and CCL2 was
highly increased, by P.g-LPS stimulation at 6 h, these in-
creases were not significant (t test, P > 0.05; Figure 2B).
The ELISA data show that CCL2 protein levels in the
gingival tissues exposed to P.g-LPS were significantly higher
than those in the control samples not injected with P.g-LPS
4 d after P.g-LPS injection (t test, P < 0.05; Figure 3A). By
contrast, the concentration of OPG in the gingival tissue
was significantly decreased in the P.g-LPS-injected tissues
compared with the control samples at 14 d after P.g-LPSas gingivalis (P.g-LPS) on the protein levels of chemokine (CeC
d (RANKL), and osteoprotegerin (OPG) in the (A) gingival tissue
me-linked immunosorbent assay and normalized to the total
als were assessed per group per endpoint. Two independent
. Data are presented as mean  standard deviation. *P < 0.05.
RANKL/OPG ratio in peri-implant gingiva 13injection (t test, P < 0.05; Figure 3A). In the bone, no
significant effect of P.g-LPS injection was found on the
CCL2, RANKL, or OPG content (Figure 3B). Consequently,
the RANKL/OPG ratio in the gingival tissues injected with
P.g-LPS was greater than that in the control tissues. Espe-
cially at 14 d after stimulation, the increase in the RANKL/
OPG ratio was significant (t test, P < 0.05; Figure 4A). By
contrast, no significant increase in the RANKL/OPG ratio
was found in the bone samples (t test, P > 0.05; Figure 4B).Expression patterns of RANKL in the gingival tissues
injected with P.g-LPS
To determine the expression patterns of RANKL in the
gingival tissue inflamed by P.g-LPS injection, dual-color
fluorescence microscopy was performed after staining for
RANKL and lymphocyte-specific CD markers. Images of the
RANKL- and CD marker-positive cells were digitally merged,
and the double-positive cells are displayed as yellow
staining (Figure 5). At 14 d, CD3-positive cells were
observed in the subepithelial connective tissue lesions of
tissue samples both in the presence and absence of P.g-LPS,
but the number of these cells in the P.g-LPS samples was
higher than that in the control samples. In addition, RANKL-
expressing cells were observed in both samples. In the
gingival tissues injected with P.g-LPS, yellow-stained RANKLFigure 4 Receptor activator of nuclear factor kB ligand/
osteoprotegerin (RANKL/OPG) ratio in the (A) gingival tissue
and (B) bone surrounding the implants was calculated. Two
independent experiments, each using the samples in triplicate,
were performed. Data are presented as mean  standard de-
viation. *P < 0.05.and CD3 double-positive cells were observed, but they were
not found in the P.g-LPS-free sections (Figure 5A). Many
CD20- or RANKL-positive cells were observed in the P.g-LPS
samples, but only a small number of CD20- and RANKL-
double-positive cells were found (Figure 5B). When the
control mouse, rabbit IgG, or mouse IgM was used, no
specific staining was seen (data not shown).Discussion
We used LPS derived from P. gingivalis in this study to
induce inflammation around a mini-implant placed in the
palatine process of rats. Several previous reports induced
experimental periodontitis using LPS at concentrations of
<10 mg/mL.27e29 Based on a preliminary experiment, we
decided to use 1 mg/mL P.g-LPS for the present study. P.
gingivalis is one of the bacteria most strongly involved in
periodontitis,30 and P.g-LPS is an agonist for TLR-2 and TLR-
4.31 The presence of TLR-2 and TLR-4, which is an LPS re-
ceptor, was found in the mucosa, particularly in the area
near the epithelium. Further, the expression of TLR-4 was
increased by P.g-LPS.31,32 Similarly, we found that TLR-4
was expressed by the cells in the gingival tissues sur-
rounding the mini-implants injected with P.g-LPS
(Figure S1). Therefore, it is possible that the rat model in
the present study was responding to the P.g-LPS. However,
the infection mechanisms in peri-implant diseases may be
different from those found in periodontitis because the
peri-implant and periodontal tissue structures, including
the organization of collagen fibers and blood vessels, are
different.
Peri-implant mucositis is a disease often managed
initially with dental treatment and does not always advance
to peri-implantitis.9 However, to inhibit the cellular re-
actions of peri-implant tissues to endotoxin containing LPS,
preventive treatment beginning as early as possible is
necessary because the endotoxin can induce bone
resorption-related molecules, as well as periodontal
disease.
During inflammation, proinflammatory cytokines, such
as TNF-a and IL-1b are secreted in abundance by immune
cells including macrophages and result in the activation of
T cells expressing RANKL and osteoclasts. TNF-a and IL-1b
are involved in both peri-implant mucositis and peri-
implantitis.33 In the present study, the gingival tissues
highly expressed those genes in response to P.g-LPS stimu-
lation, but bone did not. This suggests that the rat model
created here shows partial simulation of inflamed gingiva
without inflammation of the bone, which may correspond
to the early or acute stage of the disease. CCL2 and RANKL
are also known as monocyte chemoattractant factor and
osteoclastic differentiation-inducing factor,
respectively.34e36 P.g-LPS accelerated the expressions of
CCL2 and RANKL in the gingival tissues. However, the RANKL
expressions were not significantly changed during the
experimental period. The expression of OPG, which is a
decoy receptor for RANKL,37 was significantly decreased by
P.g-LPS at 14 d. Previous reports have suggested that the
RANKL/OPG or OPG/RANKL ratio is associated with bone
resorption in rheumatoid arthritis, osteoarthritis, hip-joint
disease, and periodontitis.38,39 In the present study, the
Figure 5 Fluorescence microscopic observation of the gingival tissue surrounding the implants. CD3, CD20, and receptor acti-
vator of nuclear factor kB ligand (RANKL) expression were visualized by staining with specific antibodies. RANKL- (green), CD3-
(red), or CD20-positive (red) cells were identified in the gingival tissues of both control and lipopolysaccharide derived from
Porphyromonas gingivalis (P.g-LPS) samples. Cells double-positive for (A) CD3 and RANKL and (B) for CD20 and RANKL are shown in
yellow. 40,6-diamidino-2-phenylindole (DAPI: blue) was used for staining nuclei. Scale bars: 20 mm.
14 T. Shuto et alRANKL/OPG ratio in the gingival tissues was significantly
increased by P.g-LPS at 14 d (t test, P < 0.05; Figure 4A),
but the ratio in bone did not increase (t test, P > 0.05;
Figure 4B), which may lead to bone resorption. This also
suggests that the rat model with P.g-LPS injections was only
partly stimulated at 14 d with inflamed gingiva, which may
correspond to the late or chronic stage of disease. A longer
duration of P.g-LPS injections would be likely to stimulate a
more severe inflammation accompanied by alveolar bone
resorption. Moreover, while P.g-LPS was used to investigate
the inflammation in the tissues surrounding the mini-
implants in the present study, the cellular reactions in
the tissues exposed to LPS from other bacteria may bedifferent. Therefore, to determine the mechanisms of peri-
implant inflammation and alveolar bone resorption, further
research is needed.
In addition to periodic radiographic examinations,40 the
early diagnosis by biochemical analysis may be required to
reduce radiological exposure. RANKL and matrix metal-
loproteinase have been detected in peri-implant crevicular
fluid.41e44 Therefore, animal models, such as the one used
in the present study, are very important and useful for
developing biochemical tests related to the pathological
conditions of peri-implant mucositis and peri-implantitis
around short- and long-term implants of peri-implant
crevicular fluid and/or tissues. Although CCL2, RANKL,
Figure 6 Schematic illustration of the hypothetical mechanisms of peri-implant disease caused by lipopolysaccharide derived
from Porphyromonas gingivalis (P.g-LPS) infection. P.g-LPS binds to toll-like receptors expressed on the epithelium and fibroblast
cells, causing these cells to secrete cytokines such as tumor necrosis factor-a and interleukin-1b. T cells infiltrate into the site of
inflammation and are activated by these cytokines. The receptor activator of nuclear factor kB ligand produced by the activated
T cells may promote osteoclastogenesis and bone resorption.
RANKL/OPG ratio in peri-implant gingiva 15and OPG molecules were detected in the crevicular fluid in
the present study, their contents varied widely (unpub-
lished data). Further studies using larger animal models or a
modified method of collection for crevicular fluid will help
to clarify this.
The results of the present study revealed that P.g-LPS
injection increased RANKL and decreased OPG, which led to
an increased RANKL/OPG ratio in the gingival tissues sur-
rounding mini-implants in the rat model. Additionally, CD3-
positive cells expressing membrane-type RANKL molecules
were found more frequently in the gingival tissues sur-
rounding the mini-implants injected with P.g-LPS than in
the control samples not injected with P.g-LPS. Therefore,
the activated T cells in peri-implant mucositis may be one
of the sources of membrane-type RANKL, and may be
involved in the bone resorption associated with the pro-
gression from peri-implant mucositis to peri-implantitis
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